Supplemental Prospectus (Form 424B3)

Filed pursuant to Rule 424(b)(3)
Registration No. 333-292647

PROSPECTUS

Virgin Galactic Holdings, Inc.

68,061,371 shares of Common Stock

Offered by the Selling Stockholders

As part of a private placement completed on December 18, 2025 (the "Previously Announced Transactions"), Virgin Galactic Holdings, Inc. (the "Company") completed the repurchase of approximately $354.6 million in aggregate principal amount of its 2.50% Convertible Senior Notes due 2027 and, in privately negotiated transactions, issued approximately $212.5 million in aggregate principal amount of its 9.80% first lien notes due 2028 (the "Notes") and warrants (the "Purchase Warrants") to purchase, at an exercise price of $6.696 per share, up to approximately 31.7 million shares of its common stock, par value $0.0001. As required by the Registration Rights Agreement entered into by the Company in connection with the Previously Announced Transactions, on January 9, 2026, the Company filed a Form S-3 Registration Statement (the "Registration Statement") that only related to the registration of the resale by the holders of the Notes and Purchase Warrants of any shares of common stock that may be issued in connection with redemption of the Notes and shares issued upon the exercise, if any, of the Purchase Warrants. The Registration Statement, of which this prospectus is a part, did not register the issuance and sale by the Company of any newly issued shares of common stock or any other securities and the Company will not receive the proceeds of the sale of the common stock, if any, by the holders.

This prospectus relates to the resale, from time to time, of up to 68,061,371 shares of our common stock, par value $0.0001 (the "Shares"), by the selling stockholders identified in this prospectus (collectively with any of the holders' transferees, pledges, donees or successors, the "Selling Stockholders"), which consists of (i) 31,734,751 shares of common stock issuable to the Selling Stockholders upon the exercise of Purchase Warrants, and (ii) 36,326,620 shares of common stock issuable to the Selling Stockholders upon a redemption by the Company of the Notes, which were issued pursuant to an Indenture, dated as of December 18, 2025 (the "Indenture"), by and among the Company, the subsidiary guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent. The Purchase Warrants and Notes described in the preceding sentence were issued in the closing of a private placement completed on December 18, 2025, pursuant to certain Subscription Agreements (the "Subscription Agreements"), by and among the Company, the subsidiary guarantors party thereto and the Selling Stockholders.

Sales of the Shares by the Selling Stockholders may occur at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The Selling Stockholders may sell Shares to or through underwriters, broker dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the Selling Stockholders, the purchasers of the Shares, or both. If required, the number of Shares to be sold, the public offering price of those Shares, the names of any underwriters, broker dealers or agents and any applicable commission or discount will be included in a supplement to this prospectus, called a prospectus supplement. See the disclosure under the heading "Plan of Distribution" elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Shares hereunder.

The Company will not receive any proceeds from the sale by the Selling Stockholders of the Shares. We will, however, receive the cash exercise price of $6.696 per share for the exercise of any Purchase Warrants.

We are paying the cost of registering the Shares covered by this prospectus as well as various related expenses. The Selling Stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of the Shares.

Our common stock is listed on the New York Stock Exchange (the "NYSE") under the symbol "SPCE." On January 22, 2026, the last reported sale price of our common stock was $3.18 per share.

Investing in our common stock involves risks. You should read carefully and consider the risks referenced under "Risk Factors" beginning on page 5 of this prospectus, as well as the other information incorporated herein by reference, before making a decision to invest in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is January 23, 2026

TABLE OF CONTENTS

ABOUT THIS PROSPECTUS

You should read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making an investment in the securities of Virgin Galactic Holdings, Inc. See "Where You Can Find More Information; Incorporation by Reference" for additional information. You should rely only on the information contained in or incorporated by reference in this prospectus or a prospectus supplement. Neither the Company nor the Selling Stockholders have authorized anyone to provide you with different information. This document may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that information contained in this prospectus, or in any document incorporated by reference, is accurate only as of any date on the front cover of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date.

Unless the context otherwise requires, we use the terms "Virgin Galactic," "company," "we," "us," and "our" in this prospectus to refer to Virgin Galactic Holdings, Inc. and its subsidiaries.

1

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and the information incorporated by reference in this prospectus contain forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this prospectus are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "might," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "seek," "would" or "continue," or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include, but are not limited to, the risks described under the heading "Risk Factors" contained in this prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus.

2

THE COMPANY

Overview

We are an aerospace and space travel company offering access to space for private individuals, researchers and government agencies. Our missions include flying passengers to space, as well as flying scientific payloads and researchers to space in order to conduct experiments for scientific and educational purposes. Our operations include the design and development, manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of our spaceflight system. Our spaceflight system was developed using our proprietary technology and processes and is focused on providing space travel experiences for private astronauts, researcher flights and professional astronaut training. We have also leveraged our knowledge and expertise in manufacturing spaceships to occasionally perform engineering services for third parties. To expand capacity, we are currently developing our next-generation spaceflight vehicles. These next-generation spaceflight vehicles, which include our Delta Class spaceships and additional launch vehicles, are expected to dramatically increase our annual flight rate. Following the completion of the non-recurring engineering work on our Delta Class spaceships, we are redeploying engineering resources to the next phase of design for our next-generation launch vehicle. In addition, we are exploring the opportunity to use a derivative model of our launch vehicle as a High-Altitude, Long-Endurance aircraft, which we believe could be utilized for several types of government and research purposes.

Private Placement

On December 9, 2025, the Company entered into the Subscription Agreements with certain investors, some or all of which are the Selling Stockholders, pursuant to which we agreed to issue and sell to the Selling Stockholders in a private placement, which closed on December 18, 2025, among other things, (a) Purchase Warrants exercisable for up to an aggregate of 31,734,751 shares of the Company's common stock, subject to customary adjustments as provided in the Purchase Warrants and (b) $212,496,000 aggregate principal amount of Notes.

The Purchase Warrants are exercisable at any time on or after June 18, 2026 until December 18, 2030 at an exercise price of $6.696 per share. A Selling Stockholder may not exercise any portion of a Purchase Warrant to the extent such exercise for common stock would cause such Selling Stockholder, together with its Attribution Parties (as defined in the Purchase Warrants), to beneficially own a number of shares of common stock which would exceed a beneficial ownership limitation of 4.9% of our then outstanding common stock following such exercise. Upon at least 61 days' prior notice from the holder to the Company, a holder may increase the applicable beneficial ownership limitation, but in no case above 9.9% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

The Company is required to redeem approximately $30.4 million of the Notes on or before September 30, 2026, and beginning on December 31, 2027 and at every calendar quarter end thereafter, the Company shall redeem approximately $10.1 million of the outstanding Notes, in each case, plus accrued and unpaid interest. Any such redemption may be made using cash, or subject to certain conditions, shares of common stock or a combination thereof. The Company's right to effect redemptions under the Indenture using shares of common stock, is subject to, among other things, that value of the shares to be issued is no less than the greater of (i) unless stockholder approval is obtained, the minimum price as of such time, in compliance with NYSE requirements, and (ii) $2.00 per share.

The Notes and Purchase Warrants issuable pursuant to the Subscription Agreements were not initially registered under the Securities Act of 1933, as amended (the "Securities Act"), and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act and Rule 501 promulgated thereunder. Pursuant to the terms of the Indenture, the Company may not issue common stock to a Selling Stockholder in connection with a redemption of the Notes to the extent that, after giving effect to such redemption, the Selling Stockholder, together with its Attribution Parties (as defined in the Indenture) collectively would beneficially own in excess of 4.9% of our then outstanding common stock following such redemption.

3

In connection with the private placement, the Company also entered into a registration rights agreement, dated December 18, 2025 (the "Registration Rights Agreement"), with certain investors, some or all of which are the Selling Stockholders, pursuant to which, among other things, the Company agreed to prepare and file with the SEC, within 45 days after the date of the Registration Rights Agreement, a registration statement to register for resale the shares of our common stock issuable upon exercise of the Purchase Warrants issued pursuant to the Subscription Agreements and the shares of our common stock issuable upon a redemption by the Company of the Notes, and to cause the registration statement to become effective within a specified time after its initial filing with the SEC.

Corporate Information

We were initially formed on May 5, 2017 under the name "Social Capital Hedosophia Holdings Corp." as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On October 25, 2019, we domesticated as a Delaware corporation and consummated the merger transactions contemplated by the Agreement and Plan of Merger, dated as of July 29, 2019, as amended on October 2, 2019, by and among us, Vieco USA, Inc., Vieco 10 Limited, TSC Vehicle Holdings, Inc., Virgin Galactic Vehicle Holdings, Inc., Virgin Galactic Holdings, LLC and the other parties thereto.

Our principal executive offices are located at 1700 Flight Way, Tustin, California 92782 and our telephone number is (949) 774-7640.

4

RISK FACTORS

Before making an investment decision, you should carefully consider the risks described under "Risk Factors" in the applicable prospectus supplement, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, if any, in light of your particular investment objectives and financial circumstances. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned elsewhere in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading "Risk Factors" included in our most recent Annual Report on Form 10-K, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, which are incorporated herein by reference, together with the other information contained in this prospectus and in our filings with the Securities and Exchange Commission (the "SEC") that we have incorporated by reference in this prospectus. We expect to update these Risk Factors from time to time in the periodic and current reports we file with the SEC after the date of this prospectus. These updated Risk Factors will be incorporated by reference in this prospectus. If any of these risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the trading price of our securities could decline, and you may lose all or part of your investment.

5

USE OF PROCEEDS

The proceeds from the resale of the Shares under this prospectus are solely for the accounts of the Selling Stockholders. We will not receive any proceeds from the sale of Shares under this prospectus. We will, however, receive the cash exercise price of $6.696 per share for the exercise of any Purchase Warrants.

6

SELLING STOCKHOLDERS

The Shares being offered by the Selling Stockholders are those issuable to the Selling Stockholders upon redemptions by the Company of the Notes and upon exercise of the Purchase Warrants. For additional information regarding the issuance of the Shares, see "The Company-Private Placement" above. We are registering the Shares in order to permit the Selling Stockholders to offer the Shares for resale from time to time. Except for the ownership of the Shares and Purchase Warrants and as otherwise described below under "Certain Relationships with the Selling Stockholders," the Selling Stockholders have not had any material relationship with us within the past three years.

In accordance with the terms of the Registration Rights Agreement with the Selling Stockholders, this prospectus generally covers the resale of the sum of (i) the maximum number of shares of common stock issuable upon exercise of the Purchase Warrants issued pursuant to the Subscription Agreements, determined as if the Purchase Warrants were exercised in full as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the Registration Rights Agreement, without regard to any limitations on the exercise of the Purchase Warrants, including the beneficial ownership limitations included therein, and (ii) the maximum number of shares of common stock issuable upon required redemptions by the Company of the Notes, determined as if the full amount required to be redeemed under the Indenture is made using shares of common stock only, without regard to any limitations on redemptions for common stock, including the beneficial ownership limitations included therein.

Under the terms of the Purchase Warrants, a Selling Stockholder may not exercise any portion of a Purchase Warrant to the extent such exercise for common stock would cause such Selling Stockholder, together with its Attribution Parties (as defined in the Purchase Warrants), to beneficially own a number of shares of common stock which would exceed a beneficial ownership limitation of 4.9% of our then outstanding common stock following such exercise. Upon at least 61 days' prior notice from the holder to the Company, a holder may increase the applicable beneficial ownership limitation, but in no case above 9.9% of the number of shares of common stock outstanding immediately after giving effect to such exercise. Pursuant to the terms of the Indenture, the Company may not issue common stock to a Selling Stockholder in connection with a redemption of the Notes to the extent that, after giving effect to such redemption, the Selling Stockholder, together with its Attribution Parties (as defined in the Indenture) collectively would beneficially own in excess of 4.9% of our then outstanding common stock following such redemption.

The table below lists the Selling Stockholders and other information regarding the beneficial ownership of our common stock as provided to the Company by each of the Selling Stockholders and is current as of January 2, 2026, unless otherwise indicated below. For purposes of the table below, we have assumed that the Selling Stockholders will be able to sell in this offering all shares of common stock issued pursuant to the Subscription Agreements or upon the exercise of any Purchase Warrants issued to the Selling Stockholder without regard to any beneficial ownership limitations. The Selling Stockholders may sell all, some or none of their shares in this offering. See "Plan of Distribution."

Beneficial ownership is determined in accordance with the rules and regulations of the SEC based on 73,129,348 shares of common stock outstanding as of January 2, 2026. In computing the number of common shares beneficially owned by a person and the percentage ownership of that person, we also deemed outstanding shares of common stock issuable upon the exercise of warrants or other convertible securities held by that Selling

7

Stockholder that are exercisable or convertible within 60 days of January 2, 2026, including the warrants, but subject to any applicable beneficial ownership limitation. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for any Selling Stockholder named below.

8

9

10

Certain Relationships with the Selling Stockholders

Repurchase Agreements

On December 18, 2025, concurrently with the completion of the private placement, the Company completed, pursuant to separate, privately negotiated repurchase agreements with certain investors, some or all of which are the Selling Stockholders, the repurchase by the Company of approximately $354.6 million in aggregate principal amount of its 2.50% convertible senior notes due 2027 (the "Repurchases") with cash proceeds from the private placement and the Registered Direct Offering (as defined below).

Registered Direct Offering

On December 18, 2025, concurrently with the completion of the private placement and the Repurchases, the Company completed, pursuant to the Subscription Agreements, the issuance and sale for cash, in a registered

11

direct offering (the "Registered Direct Offering"), of (i) 2,181,485 shares of its common stock, and (ii) pre-funded warrants to purchase 8,371,455 shares of its common stock (the "Pre-Funded Warrants").

Registration Rights Agreement

On December 18, 2025, in connection with the Subscription Agreements, the Company entered into the Registration Rights Agreement with certain investors, some or all of which are the Selling Stockholders. Pursuant to the Registration Rights Agreement, the Company agreed, among other things, to prepare and file with the SEC a registration statement to register for resale the shares of our common stock issuable upon exercise of the Purchase Warrants issued pursuant to the Subscription Agreements and the shares of our common stock issuable upon a redemption by the Company of the Notes and to cause the registration statement to become and remain effective within the time periods specified in the Registration Rights Agreement. We have also agreed, among other things, to indemnify the Selling Stockholders and their officers, directors, members, partners, agents, brokers, investment advisors and employees from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.

12

PLAN OF DISTRIBUTION

Each Selling Stockholder and any of their pledgees, donees, transferees, or any of their successors-in-interest selling Shares received from a named Selling Stockholder as a gift, partnership distribution or other permitted transfer after the date of this prospectus (all of whom may be Selling Stockholders) may, from time to time, sell any or all of the Shares covered hereby on any of the following markets or exchanges on which our common stock is listed or quoted for trading on the date in question: NYSE (or any successor thereto) or on any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:

The Selling Stockholders may also sell securities under Rule 144 promulgated by the SEC pursuant to the Securities Act, as such rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such rule ("Rule 144"), or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker dealers engaged by the Selling Stockholders may arrange for other broker dealers to participate in sales. Broker dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker dealers or other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The Selling Stockholders may also sell Shares short and deliver these securities to close out their short positions, or loan or pledge the Shares to broker dealers that in

13

turn may sell such shares. The Selling Stockholders may also enter into option or other transactions with broker dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker dealer or other financial institution of the Shares offered by this prospectus, which securities such broker dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders will act independently of us in making decisions with respect to the price, timing, manner and size of each sale of securities. Offers to purchase securities may be solicited directly by the Selling Stockholders and the sale thereof may be made by the Selling Stockholders directly to institutional investors or others. In such a case, no underwriters or agents would be involved. The Selling Stockholders may use electronic media, including the Internet, to sell offered securities directly. The Selling Stockholders may offer the securities covered by this prospectus into an existing trading market on the terms described herein or in any applicable prospectus supplement, amendment or free writing prospectus relating thereto. If the Selling Stockholders utilize a dealer in the sale of the securities in respect of which this prospectus is delivered, the Selling Stockholders may sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by the dealer at the time of resale.

The Selling Stockholders and any broker dealers or agents that are involved in selling the Shares may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker dealers or agents and any profit on the resale of the Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

A Selling Stockholder that is an entity may elect to make an in-kind distribution of the Shares to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus.

The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the Shares. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

We agreed to keep this prospectus effective until the date on which all Registrable Securities (as defined in the Registration Rights Agreement) covered by this Registration Statement have been sold hereunder in accordance with the plan of distribution disclosed herein, or otherwise cease to be Registrable Securities. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the Shares covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), any person engaged in the distribution of the Shares may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act, as applicable).

14

LEGAL MATTERS

The validity of the securities in respect of which this prospectus is being delivered will be passed upon for us by O'Melveny & Myers LLP.

EXPERTS

The consolidated financial statements of Virgin Galactic Holdings, Inc. appearing in Virgin Galactic Holdings, Inc. Annual Report (Form 10-K) as of and for the years ended December 31, 2024 and 2023, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst & Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing.

15

WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE

Available Information

We file reports, proxy statements and other information with the SEC. The SEC maintains a web site that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov.

Our web site address is www.virgingalactic.com. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus.

This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC's website, as provided above.

Incorporation by Reference

The SEC's rules allow us to "incorporate by reference" information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.

This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC:

All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the "Exchange Act" in this prospectus, prior

16

to the termination of this offering, including all such reports and other documents filed with the SEC after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to the effectiveness of such registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:

Virgin Galactic Holdings, Inc.

1700 Flight Way

Tustin, California 92782

(949) 774-7640

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.

17